88 related articles for article (PubMed ID: 7921388)
1. Chromic phosphate therapy in carcinoma of the ovary.
Goodman A; Bornstein L; Ball H; Smith DM; Bankoff M
J Am Coll Surg; 1994 Oct; 179(4):401-6. PubMed ID: 7921388
[TBL] [Abstract][Full Text] [Related]
2. Intraperitoneal radioactive phosphorus (32P) versus observation after negative second-look laparotomy for stage III ovarian carcinoma: a randomized trial of the Gynecologic Oncology Group.
Varia MA; Stehman FB; Bundy BN; Benda JA; Clarke-Pearson DL; Alvarez RD; Long HJ;
J Clin Oncol; 2003 Aug; 21(15):2849-55. PubMed ID: 12885800
[TBL] [Abstract][Full Text] [Related]
3. Pleuroperitoneal migration of intraperitoneal phosphorus-32-chromic phosphate therapy for stage I ovarian carcinoma.
Wilkinson RH
J Nucl Med; 1996 Apr; 37(4):636-9. PubMed ID: 8691256
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant intraperitoneal chromic phosphate therapy for women with apparent early ovarian carcinoma who have not undergone comprehensive surgical staging.
Soper JT; Berchuck A; Clarke-Pearson DL
Cancer; 1991 Aug; 68(4):725-9. PubMed ID: 1855171
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant therapy with intraperitoneal chromic phosphate (32P) in women with early ovarian carcinoma after comprehensive surgical staging.
Soper JT; Berchuck A; Dodge R; Clarke-Pearson DL
Obstet Gynecol; 1992 Jun; 79(6):993-7. PubMed ID: 1579329
[TBL] [Abstract][Full Text] [Related]
6. Intraperitoneal chromic phosphate therapy after second-look laparotomy for ovarian cancer.
Varia M; Rosenman J; Venkatraman S; Askin F; Fowler W; Walton L; Halle J; Currie J
Cancer; 1988 Mar; 61(5):919-27. PubMed ID: 3338057
[TBL] [Abstract][Full Text] [Related]
7. Intraperitoneal distribution imaging prior to chromic phosphate (P-32) therapy in ovarian cancer patients.
Tulchinsky M; Eggli DF
Clin Nucl Med; 1994 Jan; 19(1):43-8. PubMed ID: 8137583
[TBL] [Abstract][Full Text] [Related]
8. Use of P-32 in stage III epithelial carcinoma of the ovary.
Spanos WJ; Day T; Jose B; Paris K; Lindberg RD
Gynecol Oncol; 1994 Jul; 54(1):35-9. PubMed ID: 8020836
[TBL] [Abstract][Full Text] [Related]
9. Update on the role of radiotherapy in ovarian cancer.
Lanciano R; Reddy S; Corn B; Randall M
Semin Oncol; 1998 Jun; 25(3):361-71. PubMed ID: 9633849
[No Abstract] [Full Text] [Related]
10. Intraperitoneal chromic phosphate P 32 as salvage therapy for persistent carcinoma of the ovary after surgical restaging.
Soper JT; Wilkinson RH; Bandy LC; Clarke-Pearson DL; Creasman WT
Am J Obstet Gynecol; 1987 May; 156(5):1153-8. PubMed ID: 3578429
[TBL] [Abstract][Full Text] [Related]
11. Intraperitoneal P-32 is not an effective consolidation therapy after a negative second-look laparotomy for epithelial carcinoma of the ovary.
Peters WA; Smith MR; Cain JM; Lee RB; Yon JL
Gynecol Oncol; 1992 Nov; 47(2):146-9. PubMed ID: 1468691
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant intraperitoneal chromic phosphate therapy in a woman with early ovarian carcinoma and pelvic infection with resulting catastrophic complications.
McGowan L
Clin Nucl Med; 1994 Aug; 19(8):696-8. PubMed ID: 7955749
[TBL] [Abstract][Full Text] [Related]
13. Ovarian carcinoma: adjuvant treatment with P-32.
Reddy S; Sutton GP; Stehman FB; Hornback NB; Ehrlich CE
Radiology; 1987 Oct; 165(1):275-8. PubMed ID: 3628782
[TBL] [Abstract][Full Text] [Related]
14. Intraperitoneal chromic phosphate in ovarian cancer: risks and benefits.
Potter ME; Partridge EE; Shingleton HM; Soong SJ; Kim RY; Hatch KD; Austin JM
Gynecol Oncol; 1989 Mar; 32(3):314-8. PubMed ID: 2920951
[TBL] [Abstract][Full Text] [Related]
15. Five and ten year estimated survival and disease-free rates after intraperitoneal chromic phosphate; stage I ovarian adenocarcinoma.
Piver MS; Lele SB; Bakshi S; Parthasarathy KL; Emrich LJ
Am J Clin Oncol; 1988 Oct; 11(5):515-9. PubMed ID: 3177251
[TBL] [Abstract][Full Text] [Related]
16. Intraperitoneal radioactive chromic phosphate (P32) in the treatment of ovarian cancer.
Powell JL; Kirchner AB
J Med Assoc Ga; 1984 Jan; 73(1):21-5. PubMed ID: 6707541
[No Abstract] [Full Text] [Related]
17. CA-125 levels after surgical exploration and radioactive chromic phosphate in ovarian cancer patients.
Makhija S; Spanos WJ; Day TG; Doering D
Gynecol Oncol; 1996 Oct; 63(1):85-8. PubMed ID: 8898174
[TBL] [Abstract][Full Text] [Related]
18. Intraperitoneal chromic phosphate in peritoneoscopically confirmed stage I ovarian adenocarcinoma.
Piver MS; Barlow JJ; Lele SB; Bakshi S; Parthasarathy KL; Bender MA
Am J Obstet Gynecol; 1982 Dec; 144(7):836-40. PubMed ID: 6216811
[TBL] [Abstract][Full Text] [Related]
19. Isolated incisional metastases after intraperitoneal radioactive chromic phosphate therapy for ovarian carcinoma.
Kohler MF; Soper JT; Tucker JA; Clarke-Pearson DL
Cancer; 1991 Sep; 68(6):1380-3. PubMed ID: 1831399
[TBL] [Abstract][Full Text] [Related]
20. Ovarian nonsmall cell neuroendocrine carcinoma: a clinicopathologic and immunohistochemical study of 11 cases.
Veras E; Deavers MT; Silva EG; Malpica A
Am J Surg Pathol; 2007 May; 31(5):774-82. PubMed ID: 17460463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
